



# Assessing the clinical trial ecosystem in Europe

*Final Report*

October 2024





# Table of contents

## + Executive summary

## + Introduction

- Background and objectives of the project
- Approach and key definitions

## + Key findings

- Clinical Trial Development and Trends
- Clinical Trial Ecosystem Robustness
- Impact & Benefit of Clinical Trial Activity

## + Case studies

- Spain
- Denmark

## + Appendix

# Executive summary (1/4)

**The European clinical trial ecosystem is critical to patients, healthcare systems and society:**

- For patients, clinical trials offer early access to innovative medicines, and for rare disease patients, trials can be the only treatment option
- For health systems, clinical trials bring revenue, cost-savings, clinical skills, and staff satisfaction
- For society, clinical trials bring economic investment and GDP benefits, valued at multi-billion Euros

**Recent European level and member state policy initiatives have attempted to increase the capabilities and attractiveness of the clinical trial ecosystem.** For example, EU Clinical Trials Regulation (CTR) aimed to harmonize clinical trial capabilities across Europe, and make multi-country applications more streamlined, with the goal of boosting Europe’s competitiveness in attracting clinical trials. This goal has not yet been met. At best, Europe has held, but not improved its position.

**Our research suggests that whilst Europe is a strong performer in commercial multi-country clinical trials, it is losing global share,** particularly to Asia and other regions (falling from 25% in 2013, to 19% in 2023). Similar trends are seen in total commercial trials (single and multi-country)

- The loss of share to China could be linked to a more favorable regulatory and funding environment for Phase 1 and Cell and Gene Therapy trials, where Europe has seen a particular decline in trial starts. Late-stage clinical trials in China are often focused local/regional approvals, so may not be viewed as direct ‘competition’ to EEA and US performance.
- The loss of share to US could be driven by trial start-up timelines. This research suggests regulatory approval timelines are not the greatest differential between US and Europe, but instead, patient recruitment times in Europe may be impacting the attractiveness of Europe as a trial location. This is a multifaceted issue, but data access to enable patient-finding in niche populations could be restricting recruitment speed. However, it should be noted, most Western countries, including the US, are seeing a slow-down in clinical trial set-up and recruitment, likely reflecting increasing trial complexity, and challenges in finding suitable patients. Other factors influencing European vs. US trends include the varying levels of funding available to biotech, and wider M&A landscape, however this data have not been directly explored in this report.

**As a result of the declining share of trials, Europe has also seen a fall of the global share of patients enrolled into clinical trials. Whilst patients enrolled in European trials grew slightly during the COVID-19 pandemic, it is estimated European patient enrollment has since fallen back to below pre-pandemic levels**

# Executive summary (2/4)

**The decline in European performance is seen in key therapy areas, across phases, and commercial and non-commercial sponsors.** For example:

- There has been a decline in the clinical trial starts for oncology, neurology, rare disease, immunisation and paediatric trials.
- Some reports suggest the In-vitro Diagnostic Regulation (IVDR), which introduced more stringent requirements for the designation of Notified Bodies and affected device risk classifications, pose operational challenges for multi-region trials in oncology (and other trials highly dependent on in-vitro testing). The implications of this regulation on clinical trial activity should be closely monitored. Similarly, whilst this research focuses on trends in pharmaceutical and vaccine trials, the impact of Medical Device Regulation (MDR) on the clinical trial ecosystem should also be observed, given their relevance to clinical trial delivery.
- Europe has seen a particular decline in the proportion of Phase 1 trials. Whilst Phase 2 and 3 trials may be considered more directly impactful for patients, a reduction in Phase 1 trials could lead to a reduced ‘pipeline’ of future trials in Europe. This is particularly relevant where specialized knowledge or equipment is developed during Phase 1, which supports continued delivery of later phases.
- Europe has seen a small decline in its share of commercially-sponsored clinical trials, compared to non-commercial sponsors (49% to 47% commercial share between 2018 and 2023). This represents a comparable share and trend to the US. However, our research shows declining European share in both sponsor-types, suggesting common challenges impacting both commercial and non-commercial sponsors.

**In response to the COVID-19 pandemic and wider advances in vaccine technology, immunisation products and their associated clinical trials are a particular area of focus for global policy makers.**

- Denmark and Spain have experienced an increase in the number of immunisation trials since 2018, following a similar trend (though not as pronounced) as the rise observed in the UK during the same period. However, in 2023, overall European immunisation trial activity fell back below pre-pandemic levels, contrasting to growth in other regions. The fall in Europe appears to be driven by a decline in Phase 3 and 4 trials in this therapy area, with a geographic shift towards China and Australia.

# Executive summary (3/4)

**Across European member states, performance is more nuanced:**

- Spain has become the leading country for clinical trial starts in Europe, with a strong performance across most dimensions measured in this report. In Spain, over the past decade, the industry investment in clinical trials has risen at an average annual rate of 5.7%, climbing from EUR 479 million in 2012 to EUR 834 million in 2022. Factors attracting investment may include the capabilities of Spain's healthcare system, the successful and timely implementation of CTR (involving cross-stakeholder coordination and measurement), and an effective commercial/non-commercial clinical trial collaboration model. Notably, Barcelona hosts a major 'Prime Site' for clinical trials in Southern Europe, which has delivered increasing number of clinical trials since 2018, and plays a major role in Spain's clinical trial ecosystem.
- Meanwhile, many other European countries have seen a decline in clinical trial starts in 2023 vs. 2018. Germany has seen a decline in clinical trial starts, which has in part, been attributed to extensive negotiation times between companies and research institutions, and highly stringent data protection laws which may slow patient recruitment. Belgium has also seen a decline in trials, particularly in vaccine trials, an area in which it has historically performed strongly. Concerns regarding regulatory and ethical approval timelines, and reduced consultation with Principal Investigators have been raised by major Belgian trial centers.

**Taken together, there has been a shift in trial starts from Northern and Western Europe, towards Southern Europe, with Spain, Portugal and Greece showing strong relative performance**

# Executive summary (4/4)

**Europe remains a strong global player in clinical trials and has many strengths to build on.** Whilst more time is required to assess the full impact of CTR, certain actions should be considered now:

- **Sustain or increase government funding into health R&D and support full adoption of CTR across member states**, through co-ordination of regulatory and ethical approval processes, and practical guidance derived from real-world experience. Our research suggests government investment and policy levers are important to attracting private sector investment into clinical trial infrastructure and operations, which subsequently provides benefits to patients, healthcare systems, and supports economic growth.
- **Action should be taken ensure approvals, site-start up, and recruitment speeds do not fall further**, which could increase the ‘competitive-gap’ with the US. This a multi-faceted challenge, and requires a thorough, country-level and EU-level assessment, with a multi-stakeholder delivery. Whilst in-depth analysis is required to identify specific bottlenecks, a range of factors are seen to enhance the clinical trial ecosystem:
  - From a policy perspective, minimizing regulatory complexity, and simplifying & harmonizing contracting processes
  - Tackling clinical trial capacity & infrastructure bottlenecks, by improving site readiness, addressing staffing constraints, and reducing the variability in health system awareness of clinical trials, given the negative impacts on recruitment rates
  - Leveraging novel, patient-centric clinical trial designs to improve delivery efficiency whilst increasing attractiveness to patients
- **Lessons should be taken from Spain’s strong performance**, which is built on a cycle of early policy adoption embracing the ‘spirit’ and ‘letter’ of CTR, achieved via cross-stakeholder coordination, investment in major clinical trial sites, and strong commercial/non-commercial collaboration.

**Tentative recommendations to EU law-makers:**

The full impact of Clinical Trial Regulation is yet to be established, however, CTR has so far failed to improve Europe’s competitiveness, and there are continued challenges with CTIS implementation . Despite the ambition of harmonized standards and common procedures for regulatory and ethical approvals, the capacity and motivation at member state level to implement these changes is inconsistent. Future EU and members state funding should focus on creating “ready-to-go” clinical trial networks, that are open to working with the private sector, to attract clinical trials to Europe.



# Table of contents

## + Executive summary

## + **Introduction**

- Background and objectives of the project
- Approach and key definitions

## + Key findings

- Clinical Trial Development and Trends
- Clinical Trial Ecosystem Robustness
- Impact & Benefit of Clinical Trial Activity

## + Case studies

- Spain
- Denmark



## + Appendix

# EFPIA & Vaccines Europe (VE) sought to measure the current clinical trial ecosystem and assess its impact in Europe, to inform future policy

## Background to this project


- Clinical trials are key to driving innovation, with important impacts for patients, healthcare systems, researchers and associated R&D investment
- There is a desire across EFPIA and Vaccines Europe stakeholders to enhance European clinical trial capacity and become a hub for smarter, faster and more patient-centric trials
- However, there has been a lack of European-wide information, with suitable breadth and data granularity, to set a baseline measurement on EU clinical trial strategy and operational efficiency and to allow EU policymakers to assess policy opportunities and risks

## Objectives

- Therefore, IQVIA worked with EFPIA and VE to measure the impact of clinical trials in Europe and inform policy and operational recommendations by:
-  **Establishing a baseline to measure policy impacts**
    - Create a picture of current clinical trial development and trial trends including comparisons to other key regions
    - Use proxies and case studies to measure the clinical trial ecosystem robustness in Europe
  -  **Measuring the impact of clinical trials on patients, research and healthcare systems**
    - Use a range of proxies and case examples to demonstrate the importance and impact of the clinical trial ecosystem in Europe



# The clinical trial ecosystem has been assessed through three pillars, each comprising of qualitative and quantitative metrics



Sources: Consolidated clinical trial database<sup>2</sup>, IQVIA expertise, desk research

1. Cell and Gene Therapies  
2. CT.gov, EudraCT (EU), UMIN (Japan), ISRCTN (global), ANZCTR (Australia, New Zealand), IRCT (Iran), NTR(Netherlands), HKCT (Hong Kong CTR) and DRKS (Germany) ChiCTR (China), JapicCTI (Japan), CTRI (India), CRIS (Korea), NMRR (Malaysia), HSA CTR (Singapore),JMACCT CTR (Japan), ReBec (Brazil), PHRR (Philippines), TCTR (Thailand), SRM CTR (Russia), Mexico CTR (Mexico), LCTR (Sri Lanka), PACTR (Pan African), RPCEC (Cuba)

# The selected metrics allow a comprehensive assessment of the European ecosystem, in the context of global competition (1/2)




## Geographical definitions

- Unless specified otherwise, Europe refers to EEA. Ex-EEA countries are included in 'Other European Countries'
- EEA countries: Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Iceland, Liechtenstein and Norway
- Note: for regional-level analysis, multi-country EEA trials are counted once in the EEA total



## Comparator countries

- Switzerland and UK: co-located, non-EU countries
- Australia and Canada: high-income, non-European countries
- US and Japan: major global pharma markets
- China, South Korea: major emerging pharma markets



## Trial phase split

- Phase 2 includes Phase 1/2, Phase 2a, Phase 2b
- Phase 3 includes Phase 2/3



## Sponsor type split

- Non-commercial
- Commercial: small emerging biopharma (EBPs), EBPs, large EBPs, mid pharma, large pharma
- Combined: both commercial and non-commercial sponsors



## Clinical trials excluded from the assessment

- Medical devices trials (trials labelled as 'device' were excluded from the assessment, empty values were included)
- Suspended and terminated trials (trial labels within 'recruitment status')

# The selected metrics allow a comprehensive assessment of the European ecosystem, in the context of global competition (2/2)



## Trial initiation date ranges selection

- 2013: 'study start date' between 01/01/2013 and 31/12/2013; no filter on study end date
- 2018-2023: 'study start date' between 01/01/2018 and 31/12/2023; no filter on study end date



## Paediatric trials

- Sub-population of all paediatric trials with participants 0-18 years of age only
- Trials including adult populations are excluded



## Clinical trial timelines

- Approval, set-up and enrolment timeline estimated based on a cohort of IQVIA-conducted clinical trials; this provides a large dataset for reference, but may not be fully representative of global trends



## 'Immunisation' trial definition

- Infectious disease prophylactic vaccines (e.g., flu)
- Infectious disease therapeutic vaccines (e.g., HBV)
- Infection-related cancer vaccines, both therapeutic (e.g., CMV+ glioblastoma) and prophylactic (e.g., HPV)
- Infectious diseases prophylactic mAbs (e.g., RSV)

*Between 2020-22, trials for COVID-19 treatments had a significant impact on immunisation trends, with varying impact across geographies*

*All data accurate as of data access in April-May 2024. Clinical trial registries are subject to regular revision and updates, with greatest likelihood of revision for trials stating in most recent year e.g., 2023*

# Certain caveats should be considered when interpreting the data in this report

## 1 Data quality and completeness

Source data for this report is drawn from 22 clinical trial registries. While every effort has been made to ensure the accuracy of this data, the following limitations are known:

- The registries **may not capture every trial**
- Meta-data about trials may be **retrospectively adjusted**, if new information is received by the registry
- **Trial classification** (across dimensions such as phase, location, sponsor type) **is subject to a degree of uncertainty**.
  - For example, sponsor type analysis is based on the primary sponsor, and where possible, information on the secondary sponsor is considered. However, **absolute values should be interpreted with a degree of caution, particularly when assessing small n= numbers**

## 2 Comparison of trial totals, across dimensions

Due to the calculation methodology, the comparison of sums will not lead to the same value:

- For example, when totals are shown by **country/region** there is an ‘artificial’ inflation, because trials with sites in multiple countries/regions are counted more than once. This is intentional, to show the geographic spread.
- For **phase**, the totals are affected trials with dual phases (e.g. Ph2/3), and certain trials where phase is not coded
- For **sponsor-split**, we are again reliant on the sponsor coding; however not all trials are coded, and some are dual-coded
- For single vs. multi-country trials, a combination of these factors applies.

**Despite these caveats, absolute values have been shown in this report to provide maximum transparency. However, the focus of the analyses is on time-series trends and relative shares, where many of the data limitations are mitigated.**




# Table of contents

- + Executive summary
- + Introduction
  - Background and objectives of the project
  - Approach and key definitions
- + **Key findings**
  - **Clinical Trial Development and Trends**
  - Clinical Trial Ecosystem Robustness
  - Impact & Benefit of Clinical Trial Activity
- + Case studies
  - Spain
  - Denmark
- + Appendix

# The global clinical trial ecosystem is evolving; Europe’s share is declining, while Asia is emerging as a major location for new clinical trial starts

Number of global clinical trial starts by region (2013, 2018-2023; Phase 1-4)



Global trial starts grew year-on-year between 2013 and 2021. During this period, there has been a major evolution in geographical trial distribution. Post-2021, whilst absolute clinical trial starts have fallen back to pre-pandemic levels, relative geographic shares have remained broadly stable

- In 2013, North America, EEA, and the rest of Europe accounted for 53% of global clinical trial starts. As of 2023, this figure stood at 33%.
- During this period, Asia, and China in particular, has significantly grown its share of global clinical trial starts, with China moving from 8% of trial starts in 2013, to 29% in 2023


China’s growth may be attributed to various factors, including National Reimbursement Drug List (NRDL) expansion, a large pool of treatment naïve patients, and an increase in China-headquartered companies sponsoring trials, especially in Phase I, oncology, and cell and gene therapy. However, China’s clinical trial activity growth is primarily driven by trials conducted solely within China (single country trials).

Meanwhile, the relatively stable number of EEA trials, amidst the rising global trial numbers, has led to the EEA's share of trials decreasing from 18% in 2013, to 15% in 2018, to 9% in 2023.

Note: Medical device trials and terminated/suspended trials were excluded. ROW includes LATAM, Middle East & Africa. Rest of Europe includes Russia. Trial with sites in multiple regions were counted once for each region.  
Abbreviations: CAGR: compound annual growth rate, ROW: rest of world  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup>, 2024). IQVIA Expertise; IQVIA Institute  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# The EEA has a broadly even split of commercial and non-commercial trials; both the EEA and US have seen a slight fall in commercial share since 2018

Number of global clinical trial starts by sponsor type (2013, 2018-2023; Phase 1-4)



Global clinical trials are predominantly sponsored by non-commercial stakeholders, with a relatively stable 70% -30% split over time, however there is significant regional variation.

- Within EEA and the US, the split of commercial vs. non-commercial trials is broadly even, however, there has been a 2-percentage point decline in commercial share since 2018 in both regions
- In China, over three quarters (77%) of the trials have a non-commercial sponsor. This can be in part explained by China's focus on single-country trials, which are more likely to have a non-commercial sponsor
- In Australia, the opposite is true, where commercial trials constitute the majority. Industry reports suggest Australia is viewed as an attractive location for clinical trials, due to its medical & research expertise, dedicated infrastructure (particularly for Ph1 trials) and a streamlined regulatory and ethics approval process, and benefitting from geographic proximity to Asia


\*Commercial share within individual member states varies between ≈30-60%. European level commercial value (49%, 47%) counts multi-country EEA trials once, to allow comparison to comparator countries

Note: Combined sponsors: any trials with more than one type of sponsor (non-commercial, EBPs, mid pharma, large pharma); Medical device trials and terminated/suspended trials were excluded.

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024); MTPConnect. (2021). Australia's Clinical Trials Sector; IQVIA Expertise; IQVIA Institute

# EEA clinical trial starts were broadly stable in 2018-2022, and fell in 2023; this represents a fall in global share from 18% to 12% between 2018-2023

Number of global commercial clinical trial starts by region  
(2013, 2018-2023; Phase 1-4)



Note: Medical device trials and terminated/suspended trials were excluded. ROW includes LATAM, Middle East & Africa. Rest of Europe includes Russia. Trial with sites in multiple regions were counted once for each region.  
Abbreviations: CAGR: compound annual growth rate, ROW: rest of world  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup>, 2024).  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

Top countries holding the highest number of commercial trials  
(2018-2023, Phase 1-4)


	Country	2018	2023	CAGR
	US	1850	1719	-2%
	China	727	1412	14%
	Japan	472	546	3%
	Spain	491	485	0%
	South Korea	491	444	-2%
	Australia	436	444	0%
	UK	566	437	-5%
	Canada	473	429	-2%
	Germany	618	417	-8%

- The number of commercial clinical trial starts has increased by 38% over the last decade. Meanwhile, EEA's share of total commercial trials declined from 22% (2013), to 18% (2018), to 12% (2023)
- This performance has been driven by two key trends:
  - A flat-lining or decline in absolute trial starts, in many EEA countries
  - Significant growth in absolute trial starts in China, Japan, and other non-Western markets
- The US remains the largest single country for commercial clinical trial starts; with China rapidly closing the gap
- However, underlying these trends is an increase in the number of single country commercial trials in the US and China. Europe's fall in global share is significantly less pronounced when considering *multi-country* commercial trials only (see slide 16),



# Considering commercial *multi-country* trials, EEA performs relatively strongly, though has seen a small decline in global share from 23% to 19%, since 2018

Number of global commercial multi-country clinical trial starts by region  
(2013, 2018-2023; Phase 1-4)



When considering only multi-country commercial trials, the EEA performs strongly in the global context, though has lost share in recent years:

- EEA’s share of commercial multi-country trials (MCT) trials declined from 25% (2013), to 23% (2018) to 19% (2023), behind only North America

Compared to single-country trials, MCTs require greater coordinated activity with multiple health authorities, and management of different country timeframes for regulatory review and approval. However, MCTs can enable faster, more diverse recruitment, and accelerated multi-country regulatory submission

EEA’s activity in 2023 fell below its long-term average, which corresponds with several factors:

- Increasing clinical trial capabilities in non-EEA countries, particularly in Oceania and Asia
- EU Clinical Trial Regulation (EU CTR) entering force (1 Jan 2023) and IVDR (enters force 2022) and Medical Device Regulation (26 May 2021)
- Post-pandemic impact on healthcare systems and economies


China (and Asia more widely) represent a smaller share of global MCTs, given the large proportion of trials in China that are single-country focused.

Note: Medical device trials and terminated/suspended trials were excluded. ROW includes LATAM, Middle East & Africa. Rest of Europe includes Russia. Trial with sites in multiple regions were counted once for each region.

Abbreviations: CAGR: compound annual growth rate, ROW: rest of world

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup>, 2024).

# EEA has a relatively high share of Phase 2 & 3 trials, which are important for patients; however, the decline in Phase 1, may limit future trial opportunities



Global commercial growth has mainly been fueled by the rise in Phase 1 trials, which have seen a 4.5% growth (2018-2023 CAGR), higher compared to overall 4% growth of commercial clinical trials

In the EEA, the trend contrasts with the global picture, as most trials are in Phase 2 and 3, with a slight decrease in Phase 1 trials in 2023.

Whilst Phase 2 and 3 trials are particularly important for patients, a reduction in Phase 1 trials may lead to a reduced ‘pipeline’ of future trials, particularly in areas where specialized knowledge or equipment is required to deliver the investigational therapy, which may be established during Phase 1.

Analysis from IQVIA Institute suggests EEA has seen relative or absolute decline in most categories of trials, such as:

- Phase 1 oncology and Phase 2/3 oncology
- Cell and Gene Therapy (CaGT)
- Biosimilars
- Rare diseases

Conversely, China has grown its global share, particularly through an increase in Phase 1 oncology, Phase 2/3 oncology, and cell and gene therapy trials


Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded. Trial with sites in multiple EEA countries were counted once within EEA

Abbreviations: CAGR: compound annual growth rate


Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)

# Within EEA commercial trials, oncology remains the dominant therapeutic area; cardiovascular and rheumatology increased share, whilst neurology fell

Share of commercial clinical trials by therapy area, within EEA  
(Phase 1-4, 2018-2023)




Share of commercial clinical trials by therapy area  
(Phase 1-4, EEA, 2023)



Oncology remains the largest TA for EEA trials, accounting for more than 25% of new trial starts. Neurology is the second largest TA, though has seen a fall in activity in recent years. These trends broadly reflect the global TA picture. Infectious-disease trials are slightly lower than global average, and rheumatology higher than the global average. Recent EEA share growth is seen in cardiovascular, rheumatology and infectious diseases, at the expense of neurology and gastrointestinal trials.

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded. Trial with multiple therapy areas are counted once per therapy area.  
\*1 Oncology includes haematology-oncology treatments; \*2 The rank is based on the absolute number and the share of the given year. Abbreviations: TA: therapy area, CV: cardiovascular  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# In oncology and neurology, the EEA has experienced contrasting trends to US; IVD regulation, among other factors, may have influenced trial decisions



In the EEA, despite the ‘Beating Cancer Plan’, oncology trial starts have fallen consistently since 2021, and are now below 2018 levels. This contrasts to the US, which saw an increase in 2021, and levels have been maintained. The fall in EEA may be driven by several factors. In the EU, the in-vitro diagnostic regulation (IVDR) transition period began in 2017, which introduced more stringent requirements for the designation of Notified Bodies, with increased control and monitoring by the national competent authorities and EU Commission. This regulation affects clinical trials using in-vitro diagnostics (e.g., for patient selection, allocation and monitoring), which is particularly relevant to oncology trials, though can affect many TAs.


A fall in new starts in neurology in the EEA may be driven by a combination of local policy factors (including IVDR), but also broader industry trends (reduced biopharma R&D investment in 2022, recent R&D challenges in neurology).

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded. Trial with sites in multiple EEA countries were counted once within EEA.  
Abbreviations: TA: therapy area, IVDR: In Vitro Diagnostic Regulation  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024) | [EU Beating Cancer Plan](#)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# Europe's share of Cell and Gene Therapy trials has decreased since 2013, whilst China has experienced rapid growth in the last decade

## Cell and Gene Therapy (CaGT) spotlight

Share of cell and gene therapy trial starts by geography (2013-2023)




Europe's participation in global cell and gene therapy trials has steadily decreased since 2013.

During this period, China has seen a dramatic rise in CaGT trials since 2013, to become the leading region. This trend may be attributed to a favourable regulatory environment, funding streams, and strategic focus on these technologies

Between 2014-2022, The US share of CaGT trials declined, though the US remains the second-largest region for commercial and non-commercial trials. Since 2021, there has been a notable increase in non-commercial CaGT trials in the US, suggesting the US is increasing its focus in this area

Note: ATMP: Advanced Therapy Medicinal Products  
Abbreviations: ATMP: advanced therapy medicinal product, CaGT: cell and gene therapy  
Source: Strengthening Pathways for Cell and Gene Therapies, IQVIA Institute  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024


# The number of paediatric trials are declining in the EEA, against a backdrop of global limited growth



Globally, there has been a small increase in paediatric clinical trials across phases, with this trend primarily driven by China and other non-Western markets. Conversely, in the EEA, despite a small rise in COVID related trials during 2021-22, there has been a decline across phases since 2013

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: June 12<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# Within the EEA, there has been a decline in both commercial and non-commercial paediatric sponsored trials, suggesting systemic challenges



In the EEA, both commercial and non-commercial paediatric disease clinical trials declined over last 6 years, with commercial trials falling by 4% and non-commercial trials seeing a steeper decline (11% reduction). A decline in paediatric research has been highlighted by Evelina London Children’s Hospital, which showed:

- 30% reduction in research outputs for child health compared to pre-pandemic level, with the number of paediatric clinical trials published falling each year at an increasing rate.
- Similar trends in Europe and US, across all childhood conditions except respiratory diseases, with Europe and the UK having the greatest reductions globally

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded.

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)




# Most commercial paediatric trials are focused on infectious diseases and rare diseases; ‘paediatric-only’ oncology trials are relatively limited



## Paediatrics Spotlight

Global commercial paediatric trial starts in 2023 (Phases 1-4, top 10 TAs, n=214)



Commercial paediatric infectious disease vaccine trial starts in 2023\*

Country	#trials	%share
CN	13	23%
JP	7	12%
US	6	11%
ZA	3	5%
IN	3	5%
PH	2	4%
PL	2	4%
ES	2	4%
ID	2	4%
North America	South America	Europe
Asia	Oceania	Africa


Note: Medical device trials and terminated/suspended trials were excluded. Trial with multiple therapy areas are counted once per therapy area.

\*Trial with sites in multiple countries were counted once per country. Abbreviations: TA: therapy area

Source: Clinical Trial Repository (Access Date: April 30th 2024)



# In rare diseases, trial starts in the EEA are declining, whereas globally, trial starts remained broadly flat in 2023 compared to 2019




Globally, despite an uptick in 2021, rare disease clinical trials are also relatively flat, with 2023 showing fewer trial starts than 2019. EEA has seen a more notable decline, with 20% fewer trial stars in 2023 vs 2018. The fall is primarily driven by a reduction in Phase 1 and Phase 3 trials. Given the particular importance of emerging biopharma to rare disease trials, the global and European trends may be influenced by changes in availability of venture capital funding. However, a causal link has not been explored in this report.

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded.

Source: Clinical Trial Repository (Access Date: June 12<sup>th</sup> 2024)

# EEA rare disease trials are primarily driven by commercial sponsors, with a significant decline in non-commercial rare disease activity in 2023




Within the EEA, both commercial and non-commercial rare disease trials declined over last 6 years, with non-commercial trials seeing a steeper decline than commercial trials, suggesting systemic challenges are influencing the rare disease trial ecosystem


Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: June 12<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# Within the immunisation field, global and EEA trial starts have fallen back from a COVID peak; EEA has seen a notably large fall in Phase 3 trials

Number of global immunisation trial starts by sponsor type (2018-2023, Phase 1-4)



Number of commercial immunisation trial starts by phase (2018-2023, Phase 1-4)




The total number of immunisation clinical trial starts in 2023 has fallen back to pre-COVID levels, after major boost during 2020, 2021 and 2022 due to COVID-related research. As of 2023, commercial sponsors now account for more than 50% of new starts, having increased in absolute terms, driven by increased activity in China

Globally commercial immunisation trials growth has been driven by an increase in Phase 1 trials (+103% new starts in 2023 vs. 2018). However, EEA has seen a fall in commercial trials (-33% new starts in 2023 vs 2018). This represents a decline in global share from 17% in 2018 to 8% in 2023

EEA's fall has been driven by a decrease in the number of Phase 3 immunisation trials, whilst Phase 1 has remained stable. Phase 4 EEA immunisation trials have also fallen sharply. The trends in Phase 3 and Phase 4 should be monitored to confirm if this continues in future years

# Geographically, EEA has lost immunisation trial starts to Asia, Oceania and potentially the UK; Belgium and Finland have seen a particularly large fall

Number of global commercial immunisation trial starts for Top 10 countries (2018-2023, Phase 1-4)



Number of commercial immunisation trial starts for Top 10 EEA countries (2018-2023, Phase 1-4)

	2018	2023	CAGR
Germany	24	19	-4%
Spain	17	19	2%
France	14	12	-3%
Italy	8	8	0%
Belgium	14	8	-9%
Poland	7	7	0%
Denmark	2	6	20%
Norway	6	5	-3%
Sweden	7	4	-9%
Finland	11	3	-19%
Switzerland	3	3	0%
UK	14	23	9%

Caution required when interpreting these trends, given the small numbers of trials

Globally, there has been a relative shift in immunisation trials away from US and EEA towards China, Japan and Australia


Within EEA, most countries have seen a fall in trial starts, with Finland, Norway, Belgium, and to a lesser extent, Germany and France seeing a drop. Denmark and Spain have seen growth, and outside the EEA, UK has seen a particular increase

Belgium has historically led in per-capita immunisation trials in EEA, however stakeholders in Belgium<sup>1</sup> have raised concerns that post-CTR, the timelines for regulatory and ethical approval have significantly increased and consultation of a principal/coordinating investigator (PI) by Ethics Committees is no longer common practice.

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024); (1) \*Does not sum to total commercial immunisation trials when counted by phase, as each country is counted individually in this chart  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# Across all commercial trials in the EEA, there is variation in country-level performance; Spain recently overtook Germany in clinical trial starts

Number of EEA commercial clinical trial starts in 2018 and 2023, top 10 countries



All but three EEA countries\* saw a fall in the absolute number of trial starts in 2023 vs 2018

Spain, Germany, France and Italy remain the largest countries for clinical trial activity within the EEA


- In Spain, over the past decade, investment in clinical trials has risen at an average annual rate of 5.3%, climbing from EUR 470 million in 2011 to nearly EUR 800 million in 2021. Factors attracting investment may include quality of Spain's healthcare system, successful implementation of new European legislation on clinical trials, and an effective commercial/ non-commercial clinical trial collaboration model
- The recent decline in German trials is attributed, in part, to extensive negotiation times between companies and research institutions, and highly stringent data protection laws, which may slow patient recruitment efforts

\*Slovakia, Portugal and Greece

Note: Limited data coverage on Lichtenstein, Malta and Iceland; Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded. \*1 2018-2023 CAGR

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024); [Farnamindustria](#), [TaylorWessing](#)

# Combined, there has been a shift in trial activity towards Southern Europe, though Denmark and Belgium remain high on a per capita basis



Commercial clinical trials in EEA countries per capita (100 000) in 2023

	Country	#trials per capita
1	Denmark	2.00
2	Belgium	1.84
3	Bulgaria	1.72
4	Estonia	1.71
5	Hungary	1.68
6	Latvia	1.58
7	Czech Republic	1.35
8	Slovakia	1.28
9	Austria	1.22
10	Netherlands	1.17
	UK	0.64
	Switzerland	1.22
	US	0.51

Considering the distribution of EEA trials by sub-region, Western Europe has declined by 3 percentage points since 2018, driven by a steep decline in trial starts in Germany and Belgium, and a small decline in France.

Southern Europe has experienced a 4-percentage point increase, predominantly driven by the performance of Spain, which has attracted an increasing proportion of EEA trials across an array of TAs

Central and Eastern Europe retained a constant share of EEA trials, with Poland a top 5 EEA contributor, although CEE region has seen a particular shift away from Ph2/3 primary care-focused trials

Northern Europe (Sweden, Norway, Finland) saw a small but consistent decline since 2018

On a per capita basis, smaller countries perform strongly, with Denmark and Belgium retaining the highest level of trial starts per capita in EEA

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded. Trial with sites in multiple EEA regions were counted once per each region.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024; IQVIA Institute (Rethinking Clinical Trial Country Prioritization)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024




# Table of contents

- + Executive summary
- + Introduction
  - Background and objectives of the project
  - Approach and key definitions
- + **Key findings**
  - Clinical Trial Development and Trends
  - **Clinical Trial Ecosystem Robustness**
  - Impact & Benefit of Clinical Trial Activity
- + Case studies
  - Spain
  - Denmark
- + Appendix

# An increasing number of EEA trials are delivered in multiple countries, contrasting a recent global shift towards more single-country trials

Share of single- vs. multi-country\* commercial trials started in EEA in 2018-2023



Top 10 EEA countries holding the highest number of single country commercial trials

	Country	#trials	%share
	France	58	20%
	Germany	46	16%
	Spain	35	12%
	Netherlands	28	10%
	Italy	26	9%
	Belgium	20	7%
	Sweden	14	5%
	Denmark	13	4%
	Poland	10	3%
	Norway	8	3%

Northern Europe

Southern Europe

Central and Eastern Europe

Western Europe

In EEA, more than two-thirds of trials are ‘multi-country’ (defined as trial sites in more than one country) with this trend increasing since 2018

This finding, alongside a declining absolute number of trials, may suggest that

- There is an increasing capability to conduct trials in a range of EEA countries
- Multiple EEA countries are required to reach the desired patient population

However, other commercial and operational factors may be driving this trend

France, Germany and Spain remain the EEA countries with the greatest number of single-country trials, likely due to population size, healthcare infrastructure and research centers


Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded. Trial with sites in multiple EEA countries were counted once within EEA. \*Multi-country trials defined here as involving at least one EEA country, and not excluding those with a non-EEA country as part of the trial. NB/ A similar trend is seen when restricting multi-country trials to EEA only

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)



# Globally, US, China, India and Japan are driving the rise in single-country trials

Single- vs. multi-country commercial trials, global, Phases 1-4, in 2018-2023



Single-country commercial trials initiated in 2023, Phases 1-4, top 10 countries globally

Country	#trials	%share
China	1194	27%
US	921	21%
India	321	7%
Japan	298	7%
South Korea	179	4%
Iran	131	3%
Australia	110	2%
UK	74	2%
Canada	72	2%
Thailand	71	2%

North America

South America

Europe

Asia


Oceania

Africa

- Globally, across phases, there has been an increase in the number of single-country trials, with China, US, India, Japan driving this trend
- Approximately 50% of single-country trials are located in China and US, likely due to their large patient pool, number of local companies, regulatory requirements, and future market demand

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# EEA’s declining global share may be influenced by longer trial timelines; site start-up and recruitment are slower than the US, across therapy areas



Clinical trial set up timelines vary across regions and TAs. In this analysis, five steps were measured:

- Regulatory approval ; Ethical approval; Site ‘start-up’ Recruitment (first patient in) ; Recruitment (last patient in)

Of the five steps, site startup timeline and recruitment duration required the longest period in all three TAs explored (oncology, rare disease and infectious diseases).


Across each therapy area, EEA timelines were longer than the equivalent US values. In infectious diseases (ID), site-start up timelines in EEA were notably longer than US. Within ID, there is variation between vaccine and non-vaccine trials. Vaccine trial start-up times were significantly longer in the US (vs. non-vaccine ID trials), but only slightly longer in the EEA

Across TAs, there is country-level variation within the EEA:

- Focusing on oncology, which represents the largest TA for clinical trials, Poland, Spain and Denmark show the fastest enrolment timelines, with a similar performance to the UK.


# Within EEA, there is significant variation across countries, with Poland, Spain and Denmark showing fast recruitment rates

Clinical trial setup timelines within EEA and European comparator countries



Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# However most Western countries, including the US, are seeing a slow-down in trial set-up and recruitment, potentially driven by increased trial complexity



Clinical trial set-up timeline has been increasing since 2018, in most Western markets. This may be attributed to increasingly complex trials, with a wider set of endpoints, with more granular patient recruitment requirements, and longer negotiations with hospital centers

Between 2021-22, Switzerland saw a notable significant increase in set-up timelines. As a non-EU country, Switzerland has not adopted EU's Clinical Trial Regulation, and follows local clinical trial regulations and processes

Within major EEA countries, Spain retains the shortest trial set-up timelines, though faced a 25% deceleration since 2018

Whilst also slowing, in absolute terms, US and Australia have faster timelines than most major EEA countries, with US increasing the gap to the EEA in recent years



# Table of contents

- + Executive summary
- + Introduction
  - Background and objectives of the project
  - Approach and key definitions
- + **Key findings**
  - Clinical Trial Development and Trends
  - Clinical Trial Ecosystem Robustness
  - **Impact & Benefit of Clinical Trial Activity**
- + Case studies
  - Spain
  - Denmark
- + Appendix

# Clinical trials are extremely valuable to patients, providing early access to medicines and the opportunity to push boundaries of scientific knowledge

## Impact on patients




Source: 1. [CRUK](#), 2. [NIH](#) 3. [NORD](#)

# In recent years, the EEA has seen a decline in the number of patients enrolled into clinical trials, contrasting to global growth

## Impact on patients

Total patient numbers enrolled into commercial global, EEA-only and EEA-included trials (2018-2023)



Between 2018 and 2023, global enrollment of patients into commercial clinical trials increased by 12%, despite falling back from the major boost seen during the COVID pandemic

Conversely, in the EEA, there has been a decline in the number of patients enrolled in ‘EEA-only’ trials (-20%) and ‘EEA-included trials’ (-22%)


These trends follow a similar pattern to clinical trial starts, confirming that the fall in trials has not been compensated by ‘larger’ trials with greater number of enrolled patients

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# For patients with rare diseases, a decline in patient numbers is particularly concerning, given the critical role trials play in providing treatment options

## Impact on patients - Rare Disease Spotlight


Share of rare diseases with and without approved treatment options



Approximately 30 million individuals in Europe are affected by rare diseases, and rare conditions are often associated with a high disease burden, with nearly 50% of cases diagnosed in early childhood

The development of new therapies is essential for improving patient outcomes, with clinical trials frequently serving as the primary option in the 95% of rare diseases with no approved treatments

Number of patients enrolled into rare disease trials EEA and North and South America in 2019-2023



Thousands of rare disease patients are receiving treatment options through clinical trials each year in the EEA and US, so a decline in rare disease trials would limit options for many patients

Note: Number of patients enrolled in rare diseases clinical trials: multi-country trials including sites in other than indicated regions were excluded

Sources: [NORD Rare Disease](#); [FDA](#); [European Commission](#)



# Healthcare systems may miss out on revenue, cost-savings, clinical skills, and staff satisfaction associated with clinical trials

## Impact on healthcare systems

Clinical trials bring direct financial benefit to healthcare systems through two mechanisms

- Revenue derived from running clinical trials
- Cost-savings associated with ‘research-access’ to innovative medicines

Based on studies of healthcare system performance, research and clinical trial activity is seen to impact:



**Job satisfaction:** staff involved in research have greater job satisfaction and staff turnover is lower in research active hospital groups



**Clinical outcomes:** research active hospitals have lower mortality rates (extending beyond research participants)



**Healthcare performance:** operational improvements have been seen from the creation of academic research placements



Clinical academic research is associated with **improved patient and carer experiences.**



In 2018/19, the NHS received on average £9,000 per patient recruited to a commercial clinical trial and saved over £5,800 in drug costs for each of these patients. This equates to income of £355 million and cost savings of £28.6 million in 2018/19.



Scaled to EEA level, this suggests European health systems benefit from 1-1.5bn EUR from clinical trial payments and drug cost savings.


# However, for sites able to capitalise on opportunities, clinical trials drive financial benefits and direct opportunities cutting-edge patient care

## Impact on healthcare systems – Positive trends at a major Spanish site


Vall d’Hebron is a major hospital and academic campus in Barcelona, seen as a leader in clinical research. **Contrasting to the wider EEA trend, the center has seen growth in clinical trials since 2019.** Hospital beds are located close to laboratories, supporting direct translation research. The center is viewed positively by industry leaders as a key site for trial delivery

### Key statistics


Active and new clinical studies per year



Trial split by phase




Trial split by TA group (%)



Sources: [Vall d’Hebron](#)

# A thriving clinical trial ecosystem brings multi-billion Euro economic benefit, but requires coordinated government investment and policy implementation

## Impact on economy and society



Sources: 1. Copenhagen Economics; 2. NIHR (UK); 3. Vall d'Hebron Hospital 4. (a) (b) (c) .5 Office of Life Sciences (UK); 6. Farmaindustria; 7. UK Government (Lord O'Shaughnessy review); IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024




# Table of contents

- + Executive summary
- + Introduction
  - Background and objectives of the project
  - Approach and key definitions
- + Key findings
  - Clinical Trial Development and Trends
  - Clinical Trial Ecosystem Robustness
  - Impact & Benefit of Clinical Trial activity
- + **Case studies**
  - Spain
  - Denmark
- + Appendix



# Spain is a strong EEA performer, with trials remaining stable and significant investment in key sites


Top 5 research centers in Spain  
(number of ongoing trials)



Spanish clinical trial sites in numbers

Total number of sites	Number of cities with sties		
168	69		
#trials per site	Initiated 2018-2024	Ongoing	Planned
Mean	105	61	2.25
Median	48	29	1

Clinical trial starts in Spain, by sponsor type



- Over 80% trials in Spain are sponsored by **commercial stakeholders** (higher than ~75% in EEA), with multi-sponsor **collaborations increasing**
- Commercial clinical trials** represent an **investment of EUR 834 million in 2022** (60% of total R&D investment is the sector)\*<sup>1</sup>

## Country-specific insights

- Spain has taken a **proactive, coordinated, cross-stakeholder approach** to building its clinical trial ecosystem. Over the past decade, **investment in clinical trials has risen at an average annual rate of 5.7%**, climbing from EUR 479 million in 2012 to nearly EUR 834 million in 2022
- Factors attracting investment into Spain may include:
  - **Quality of Spain's healthcare system**, e.g., hospital infrastructure
  - **Successful implementation of new European legislation** around clinical trials and adaptation of its own legislation accordingly
  - Effective **commercial/ non-commercial clinical trial collaboration model**
- There are key research centers** in several major cities, and overall **>3 research centers per 10 000 km<sup>2</sup> area** of the country
- Within **immunisation**, excluding COVID-19 pandemic years, **~20 trials per year** are initiated in Spain


Note: FPI: first patient in; Top 5 research centres: holding the highest number of clinicals; \*<sup>1</sup> 2018-2023 CAGR, commercial trials.

Sources: 1. PharmaBoardroom; 2. Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)



# Spain has shown broad therapy area growth, and faster than EEA average site-start up and recruitment timelines

Clinical trial starts in Spain, by phase




- Across last 6 years, the **phase distribution in Spanish clinical trials has been stable and follows EEA trends**
- A **slight increase in share** has been observed in **Ph1 and Ph4** trials

Top 10 TAs in Spanish clinical trials

Therapy area	2018	2023	CAGR*
Oncology	216	186	-2%
Rheumatology	18	43	16%
Neurology	51	41	-4%
Cardiovascular	21	40	11%
Dermatology	29	33	2%
Respiratory	20	24	3%
Infectious Disease	23	23	0%
Medical Genetics – Rare	14	23	9%
Hematology	19	21	2%
Nephrology	11	19	10%

- Following global and EEA trends, **oncology remains the largest TA** in trials in Spain both in share and absolute numbers
- In line with EEA trends, both **oncology and neurology declined** over the last 6 years (2018-2023 CAGR: -2% and -4%, respectively)
- A **significant increase** has been observed in **CVD, nephrology and medical genetics – rare** (positive 2018-2023 CAGR 9-11%)

Clinical trial set up timelines in Spain and EEA



- **Trial approval timeline** in both oncology and infectious diseases has been **comparable to EEA**, however **slightly lower within infectious diseases** (this might be attributed to accelerated approvals for COVID-19 trials)
- **Site startup timeline is faster in Spain** compared to average EEA timelines in both oncology and infectious diseases by 11-12%
- Time to **first patient in** within **oncology** trials is **significantly lower** (by ~40%) than mean EEA time

Note: FPI: first patient in; 2018-2023 CAGR, commercial trials.  
Sources: 1. PharmaBoardroom; 2. Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# Denmark is a leading country in number of trials per capita, leveraging a relatively high number of research centres


Top 5 research centers in Denmark  
(number of ongoing trials)



Danish clinical trial sites in numbers

Total number of sites	Number of cities with sties		
27	15		
#trials per site	Initiated 2018-2024	Ongoing	Planned
Mean	37	24	2.25
Median	12	6	1.5

Clinical trial starts in Denmark, by sponsor type



- Overall, the **number of clinical trials in Denmark decreased** from 2018, though in line with EEA average
- In Denmark, **non-commercial** sponsors hold **significantly higher trial share** than average EEA share (~25%)
- **Trials held in collaboration** of multiple sponsors **increase** in share **reaching 22% in 2023**

## Country-specific insights

- Like Spain, Denmark has taken proactive, cross-stakeholder actions to ensure the country is an attractive location for clinical trials
- Denmark is perceived to have a strong clinical trial ecosystem, with relatively fast approval times, a range of clinical trial networks, and access to a range of real-world datasets to support patient-finding. Despite a fall in absolute number of trial starts in 2023, Denmark remains the **leading European country in number of clinical trial starts per capita**
- **Key research centers** in Denmark are evenly **distributed across the country** and overall there are **over 6 research centers per 10 000 km<sup>2</sup>** area of the country
- Within **immunisation**, excluding COVID-19 pandemic years, **10 trials per year** are initiated, a relatively strong performance given the country size


Note: FPI: first patient in; 2018-2023 CAGR, commercial trials.  
Sources: 1. [InvestinDK](#); 2. Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024





# Therapeutic area trends in Denmark reflect EEA trends, and significant efforts have been made to meet target approval timelines under CTR

Clinical trial starts in Denmark, by phase



- Across last 6 years, the **phase distribution in Danish clinical trials has remained broadly consistent**
- In 2023, there was a drop in Phase 1 starts, mirroring a wider EEA trend


Top 10 TAs in Danish clinical trials

Therapy area	2018	2023	CAGR*
Oncology	47	37	-4%
Cardiovascular	11	18	9%
Neurology	18	13	-5%
Medical Genetics – Rare	7	11	8%
Endocrinology	10	10	0%
Rheumatology	2	9	28%
Dermatology	12	8	-7%
Respiratory	11	8	-5%
Nephrology	3	4	5%
Infectious diseases - vaccine	2	3	7%

Legend: Positive CAGR (green), Stable CAGR (yellow), Negative CAGR (pink)

- Following global and EEA trends, **oncology remains the largest TA** in trials in Denmark both in share and absolute numbers
- In line with EEA trends, both **oncology and neurology declined** over the last 6 years (2018-2023 CAGR: -4% and -5%, respectively)
- A **significant increase** has been observed in **rheumatology, CVD, and medical genetics – rare** (positive 2018-2023 CAGR 9-28%)

Clinical trial approval timelines in Denmark



- Denmark has taken steps to ensure clinical trial approvals are timely.
- In Denmark, **100% of clinical trial submissions** have been granted the decision within the estimated CTR timeline
- While the proportion of submissions processed within CTR timelines increased, the share of submissions processed within IVDR timeline slightly declined

Note: FPI: first patient in; 2018-2023 CAGR, commercial trials. Abbreviations: MD: Medical Devices, IVDR: In Vitro Diagnostic Medical Devices Regulation, Dir: previous clinical trial regulations, CTR: Clinical Trials Regulation  
Sources: 1. PharmaBoardroom; 2. Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024) 3. De Videnskabetiske Medicinske  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024





# Appendix

- + Further details on methodology
- + References
- + Data tables

# Data from the following Clinical Trial Repositories have been utilised in this analysis

Database	Region / Country
CT.gov	Global
EudraCT	EU
UMIN, JAPIC, JMAC	Japan
ISRCTN	Global
ANZCTR	Australia, New Zealand
IRCT	Iran
NTR	Netherlands
HKCT	Hong Kong
DRKS	Germany
ChiCTR	China
CTRI	India

Database	Region / Country
CRiS	Korea
NMRR	Malaysia
HAS CTR	Singapore
ReBec	Brazil
PHRR	Philippines
TCTR	Thailand
SRM CTR	Russia
Mexico CTR	Mexico
SLCTR	Sri Lanka
PACTR	Africa
RPCEC	Cuba

# A range of other public sources have been referenced throughout this report

- IQVIA Institute Reports:
  - Strengthening Pathways for Cell and Gene Therapies
  - Rethinking Clinical Trial Country Prioritization
- Australia's Clinical Trials Sector
- European Commission: Europe's Beating Cancer Plan
- The impact of EU-CTR. An emergency signal from 2 large academic vaccine trial centers in Belgium 22MAY2024.docx (politico.eu)
- Distefar: Spain registers more than 900 clinical trials in 2022, above pre-pandemic levels
- TaylorWessing: Current developments in the field of clinical drug trials in Germany - adjusting parameters to shorten procedures before the start of a clinical trial
- Office of Life Sciences, UK Government
- The Association of the British Pharmaceutical Industry
- Clinical trial phase timelines
- NIH
- NORD: National Organisation for Rare Diseases
- FDA
- Rare diseases - European Commission (europa.eu)
- Improvements in Medical Recruitment
- Research Activity
- HCP Collaborative Project
- Clinical Academic Activity
- Vall d'Hebron
- Office of Life Sciences UK Government;
- UK Government;
- Copenhagen economics
- PharmaBoardroom
- De Videnskabsetiske Medicinske

# In addition to the core metrics, a selection of other metrics were explored, but analysis was not included in this report given data limitations

## Number and proportion of clinical trials terminated early and rationale

- Our initial data analysis suggests a decline in early terminated trials over last three years. Secondary sources<sup>1</sup> support this trend, showing:
  - A decrease in the number of trial terminations citing low enrolment. This may be due to improved patient engagement approaches
  - Despite this, low enrolment remains greatest source of termination, particularly in oncology and CNS, potentially due to increasingly narrow recruitment criteria
  - A growing proportion of terminated commercially sponsored trials now include a rationale, suggesting sponsors are becoming more transparent with this information

## Number of first in human trials (FIH)

- First in human (FIH) trials are not widely coded in clinical trial registries
- Key word search (first in human', 'first in man') suggested a significant growth in FIH trials recent years, however this is inconsistent with secondary data sources, and therefore this metric has not been explored further in this report

## Number of first in class trials (FIC)

- First in class (FIC) trials are not widely coded in clinical trial registries
- The FDA publishes an annual list of 'FIC' trials, whilst the EMA does not appear to publish equivalent information.
- Through this project, selected data has been collected from secondary sources, however this is metric has not been explored further in this report

## Number of human challenge trials

- 'Human challenge' trials are not widely coded in clinical trial registries
- Number of human challenge trials (CHIM) were identified using key word search ('human challenge', 'controlled human infection model', 'CHIM') in titles of trials within ct.gov.
- The values do not align with other published sources e.g. PubMed studies, suggesting other data extraction methods are required
- This metric has therefore not been explored further in this report

Source: [1](#)

# Data Tables

- **Pillar 1 metrics global**

- Global clinical trials by region
- Multi-country trials by region
- Trials by sponsor type, by region
- Trials by sponsor type
- Global trials by phase
- Commercial trials by region
- Commercial multi-country trials by region
- Commercial trials by phase
- Single country trials
- Single country vs multi country, by phase
- Commercial trials by country
- Commercial trials by therapeutic area

- **Pillar 1 metrics EEA**

- EEA sponsor type
- EEA phase split
- EEA sponsor type, by phase
- EEA single vs. multi-country split, by phase
- EEA top therapeutic areas (US comparison)
- EEA markets and comparators
- EEA per capita performance
- EEA sub-regional performance

- Global paediatric and paediatric/adult trials
- Global and EEA paediatric-only trials
- EEA paediatric trials, commercial vs. non commercial
- Paediatric trials global therapeutic area split
- Global and EEA rare disease trials
- EEA commercial and non-commercial rare disease trials

- **Pillar 2**

- Clinical trial enrollment: patient numbers (global)
- Clinical trial enrollment: patient numbers (EEA deep dive)
- Global enrolment speeds
- Oncology EEA country level enrollment
- Infectious diseases EEA country level enrollment

- **Immunisation trials**

- Total immunisation trials by sponsor
- Trials by phase (commercial vs. non commercial split)
- EEA commercial immunisation starts
- EEA phase split



## Pillar 1 metrics global



# Global clinical trials by region

Number of global clinical trial starts by region (2013, 2018-2023; Phase 1-4)

Region	2013	2018	2019	2020	2021	2022	2023
North America	3392	4180	4116	4156	4684	4113	3825
EEA	2424	2662	2622	2737	2983	2449	1978
Rest of Europe	1227	1650	1699	1612	1808	1746	1520
China	1052	3238	4844	6732	7473	7010	6283
Asia (excl. JP&CN)	2360	3445	4541	6122	6425	5748	5868
Japan	1527	1117	862	807	1059	706	808
Oceania	531	613	685	806	927	606	562
ROW	742	1317	1420	1638	1699	1510	1197
Total	13255	18222	20789	24610	27058	23888	22041

Note: Medical device trials and terminated/suspended trials were excluded. ROW includes LATAM, Middle East & Africa. Rest of Europe includes Russia. Trial with sites in multiple regions were counted once for each region.

Abbreviations: ROW: rest of world

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup>, 2024).



# Multi-country trials by region

Number of global multi-country clinical trial starts by region (2013, 2018-2023; Phase 1-4)

Region	2013	2018	2019	2020	2021	2022	2023
North America	678	972	953	1025	1252	1087	912
EEA	811	980	990	996	1196	1035	769
Rest of Europe	576	704	681	648	815	677	537
China	83	152	156	190	253	250	225
Asia (excl. JP&CN)	336	416	417	493	568	475	439
Japan	117	204	237	252	303	270	253
Oceania	263	354	353	423	497	421	372
ROW	329	365	405	473	529	457	398
Total	3193	4147	4192	4500	5413	4672	3905

Note: Medical device trials and terminated/suspended trials were excluded. ROW includes LATAM, Middle East & Africa. Rest of Europe includes Russia. Trial with sites in multiple regions were counted once for each region.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup>, 2024).





# Trials by sponsor type, by region

Number of global clinical trial starts by sponsor type (2013, 2018-2023; Phase 1-4)

Sponsor type	2013	2018	2019	2020	2021	2022	2023
Non-commercial	7736	10402	12737	15958	16661	14726	14174
Commercial	4183	5113	5336	5709	6972	6668	5978
Combined	138	319	391	462	504	393	304
Total	12057	15834	18464	22129	24137	21787	20456

Number of clinical trial starts in key global regions by sponsor type (2018, 2023; Phase 1-4)

Region	 EEA	 US	 China	 Australia	 Brazil					
Sponsor type	2018	2023	2018	2023	2018	2023	2018	2023	2018	2023
Non-commercial	1248	963	1906	1796	2510	4827	125	85	187	83
Commercial	1274	902	1735	1548	577	1198	370	352	122	120
Combined	82	66	115	171	174	279	66	92	19	27
Total	2604	1931	3756	3515	3261	6304	561	529	328	230

Note: Combined sponsors: any trials with more than one type of sponsor (non-commercial, EBP, mid pharma, large pharma); Medical device trials and terminated/suspended trials were excluded.  
 Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
 IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# Trials by sponsor type

Number of clinical trial starts in key global regions by sponsor type (2018, 2023; Phase 1-4)

Region	 EEA	 US	 China	 Australia	 Brazil					
Sponsor type	2018	2023	2018	2023	2018	2023	2018	2023	2018	2023
EBP small	964	966	868	940	259	685	169	186	25	22
EBP	270	144	115	89	97	247	29	38	2	9
EBP large	111	90	56	30	24	65	6	3	1	1
Mid	369	172	146	87	104	126	27	12	8	7
Large	1972	1167	550	402	93	75	139	113	74	59
Multiple sponsor types	701	1029	115	171	174	279	66	92	27	4
Total	4387	3568	1850	1719	751	1477	436	444	141	147

Note: Medical device trials and terminated/suspended trials were excluded. Combined sponsors: any trials with more than one type of sponsor (non-commercial, EBPs, mid pharma, large pharma).  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup>, 2024).



# Global trials by phase

*Commercial and non-commercial trial starts by phase (2013, 2018-2023)*

Commercial trial starts							
Phase	2013	2018	2019	2020	2021	2022	2023
Phase 1	1367	1982	2263	2291	2813	2776	2580
Phase 2	1210	1701	1724	1943	2378	2236	1890
Phase 3	1115	1212	1205	1335	1557	1446	1290
Phase 4	491	537	535	602	728	603	522
Total	4183	5432	5727	6171	7476	7061	6282

Non-commercial trial starts							
Phase	2013	2018	2019	2020	2021	2022	2023
Phase 1	1022	1514	2728	3807	3575	3520	3210
Phase 2	3904	5294	5525	6506	6989	5968	5346
Phase 3	1305	1568	2123	3068	3076	2695	3123
Phase 4	1505	2026	2361	2577	3021	2543	2495
Total	7736	10402	12737	15958	16661	14726	14174

Note: Combined sponsors: any trials with more than one type of sponsor (non-commercial, EBPs, mid pharma, large pharma); Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# Commercial trials by region

Number of global commercial clinical trial starts by region (2013, 2018-2023; Phase 1-4)

Region	2013	2018	2019	2020	2021	2022	2023
North America	1630	2008	1957	2029	2404	2183	1835
EEA	1287	1400	1396	1389	1602	1396	997
Rest of Europe	808	1150	1164	1100	1277	1254	1138
China	305	728	956	1103	1493	1440	1417
Asia (excl. JP&CN)	643	1063	1101	1389	1674	1500	1188
Japan	441	474	506	489	664	493	546
Oceania	330	473	480	564	643	517	473
ROW	358	407	408	482	561	482	396
Total	5802	7703	7968	8545	10318	9265	7990

Note: Medical device trials and terminated/suspended trials were excluded. ROW includes LATAM, Middle East & Africa. Rest of Europe includes Russia. Trial with sites in multiple regions were counted once for each region.  
Abbreviations: ROW: rest of world  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup>, 2024).  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# Commercial multi-country trials by region

Number of global commercial multi-country clinical trial starts by region (2013, 2018-2023; Phase 1-4)

Region	2013	2018	2019	2020	2021	2022	2023
North America	596	868	867	904	1143	1010	834
EEA	714	869	893	862	1053	941	697
Rest of Europe	518	644	611	576	745	623	493
China	70	144	144	180	244	237	218
Asia (excl. JP&CN)	294	367	370	422	518	440	403
Japan	108	196	227	245	292	265	248
Oceania	231	322	319	373	440	392	348
ROW	286	315	337	394	439	402	335
Total	2817	3725	3768	3956	4874	4310	3576

Note: Medical device trials and terminated/suspended trials were excluded. ROW includes LATAM, Middle East & Africa. Rest of Europe includes Russia. Trial with sites in multiple regions were counted once for each region.

Abbreviations: ROW: rest of world

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup>, 2024).



# Commercial trials by phase

Number of global commercial clinical trial starts by phase (2013, 2018-2023; Phase 1-4)

Phase	2013	2018	2019	2020	2021	2022	2023
Phase 1	1410	1982	2263	2291	2813	2776	2580
Phase 2	1287	1701	1724	1943	2378	2236	1890
Phase 3	1157	1212	1205	1335	1557	1446	1290
Phase 4	519	537	535	602	728	603	522
Total	4373	5432	5727	6171	7476	7061	6282

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# Single country trials

Number of global, single- vs. multi-country commercial trial starts (2018-2023; Phase 1-4)

Trial location	2018	2019	2020	2021	2022	2023
Single-country	3974	4200	4587	5440	4950	4402
Multi-country	1150	1172	1193	1456	1290	1042
<b>Total</b>	<b>5124</b>	<b>5372</b>	<b>5780</b>	<b>6896</b>	<b>6240</b>	<b>5444</b>

Number of single-country commercial trial starts in 2023, top 10 countries globally (Phases 1-4)

Country	#trial starts	Global % share
China	1194	27%
US	921	21%
India	321	7%
Japan	298	7%
South Korea	179	4%
Iran	131	3%
Australia	110	2%
UK	74	2%
Canada	72	2%
Thailand	71	2%

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded.  
 Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
 IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# Single country vs multi country, by phase

*Number of single-country trial starts by phase*

Region	Global					
Phase	2018	2019	2020	2021	2022	2023
Phase 1	1723	1957	1944	2410	2265	2079
Phase 2	1139	1128	1298	1522	1373	1191
Phase 3	658	673	813	871	800	712
Phase 4	454	442	532	637	512	420
<b>Total</b>	3974	4200	4587	5440	4950	4402

*Number of multi-country trial starts by phase*

Region	Global					
Phase	2018	2019	2020	2021	2022	2023
Phase 1	173	176	209	219	228	174
Phase 2	422	445	485	598	517	433
Phase 3	479	468	432	561	479	398
Phase 4	76	83	67	78	66	37
<b>Total</b>	1150	1172	1193	1456	1290	1042

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded.

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)





# Commercial trials by country

*Number of clinical trial starts in top 10 countries globally and 2018→2023 trend*

Country	2018	2019	2020	2021	2022	2023	2018-2023 CAGR
US	1850	1794	1920	2228	2051	<b>1719</b>	-2%
China	727	956	1103	1492	1440	<b>1412</b>	14%
Russia	592	634	610	596	557	<b>561</b>	-1%
Japan	472	506	489	663	493	<b>546</b>	3%
Spain	491	544	548	688	607	<b>485</b>	0%
South Korea	491	483	497	590	489	<b>444</b>	-2%
Australia	436	446	530	607	485	<b>444</b>	0%
UK	566	528	495	630	566	<b>437</b>	-5%
Canada	473	466	433	583	474	<b>429</b>	-2%
Germany	618	600	580	665	623	<b>417</b>	-8%
<b>EEA*</b>	<b>1253</b>	<b>1252</b>	<b>1277</b>	<b>1484</b>	<b>1282</b>	<b>920</b>	<b>-6%</b>

\*Limited data coverage on Lichtenstein, Malta and Iceland

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded. Trial with sites in multiple EEA countries were counted once within EEA

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)



# Commercial trials by therapeutic area

Number of global commercial clinical trial starts by therapy area (2018-2023; Phase 1-4)

Therapy Area	2018	2019	2020	2021	2022	2023
Oncology*	1282	1374	1417	1873	1819	1738
Neurology	489	525	498	587	551	448
Endocrinology	336	360	300	351	389	422
Cardiovascular	273	267	293	307	371	387
Rheumatology	250	281	252	370	399	381
Infectious Disease	269	293	861	673	514	376
Dermatology	297	279	251	335	302	299
Infectious disease vaccine)	153	198	316	426	365	263
Respiratory	218	200	378	282	256	234
Ophthalmology	203	215	237	265	262	224

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded. Trial with multiple therapy areas are counted once per therapy area.

\*Oncology includes haematology-oncology treatments

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)



## **Pillar 1 metrics EEA**



# EEA sponsor type

Number of EEA clinical trial starts by sponsor type (2013, 2018-2023; Phase 1-4)

Sponsor type	2013	2018	2019	2020	2021	2022	2023
Non-commercial	1008	1248	1213	1333	1357	1033	963
Commercial	1241	1274	1269	1262	1479	1280	902
Combined	70	82	76	86	85	76	66
Total	2319	2604	2558	2681	2921	2389	1931

Note: Combined sponsors: any trials with more than one type of sponsor (non-commercial, EBPs, mid pharma, large pharma). Phase 1-4 trials considered. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)



# EEA phase split

Number of EEA commercial clinical trial starts by phase (2013, 2018-2023; Phase 1-4)

Phase	2013	2018	2019	2020	2021	2022	2023
Phase 1	235	157	209	199	222	200	132
Phase 2	401	524	482	510	601	501	373
Phase 3	472	439	411	396	489	442	327
Phase 4	133	133	150	172	172	139	88
Total	1241	1253	1252	1277	1484	1282	920

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# EEA sponsor type, by phase

*Commercial and non-commercial EEA trial starts by phase (2013, 2018-2023)*

Commercial trial starts						
Sponsor type	2018	2019	2020	2021	2022	2023
Phase 1	157	209	199	222	200	132
Phase 2	524	482	510	601	501	373
Phase 3	439	411	396	489	442	327
Phase 4	133	150	172	172	139	88
Total	1253	1252	1277	1484	1282	920

Non-commercial trial starts						
Sponsor type	2018	2019	2020	2021	2022	2023
Phase 1	97	84	89	92	88	69
Phase 2	662	644	666	678	534	476
Phase 3	208	227	279	244	190	212
Phase 4	281	258	299	343	221	206
Total	1248	1213	1333	1357	1033	963

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# EEA single vs. multi-country split, by phase

*Number of single-country trial starts by phase*

Region	EEA					
Phase	2018	2019	2020	2021	2022	2023
Phase 1	148	178	142	163	146	102
Phase 2	225	173	186	201	149	95
Phase 3	63	53	67	59	61	36
Phase 4	84	85	117	112	90	58
Total	520	489	512	535	446	291

*Number of multi-country trial starts by phase*

Region	EEA (includes trials with sites within EEA and other global regions)					
Phase	2018	2019	2020	2021	2022	2023
Phase 1	97	118	120	131	120	73
Phase 2	306	312	327	403	358	281
Phase 3	379	358	332	432	382	292
Phase 4	54	68	57	63	50	31
Total	836	856	836	1029	910	677

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded. Trial with sites in multiple EEA countries were counted once within EEA.

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)

# EEA top therapeutic areas (US comparison)

Number of EEA commercial clinical trial starts by therapy area (2018-2023; Phase 1-4)



Therapy Area	2018	2019	2020	2021	2022	2023
Oncology	376	384	407	457	385	292
Neurology	142	129	122	143	131	82
Rheumatology	56	78	60	100	101	80
Cardiovascular	70	60	77	77	79	69
Dermatology	101	79	71	79	66	66
Endocrinology	89	101	77	73	75	53
Respiratory	73	67	104	77	77	53
Infectious Disease	43	63	162	101	74	43
Medical Genetics - Rare	31	33	37	54	57	43
Gastrointestinal	63	40	51	55	53	36

Number of US commercial clinical trial starts by therapy area (2018-2023; Phase 1-4)



Therapy Area	2018	2019	2020	2021	2022	2023
Oncology	1157	1228	1269	1654	1520	1446
Neurology	456	479	449	523	462	379

Note: Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded. Trial with multiple therapy areas are counted once per therapy area.

\*Oncology includes haematology-oncology treatments

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)





# EEA markets and comparators (1/3)

Number of EEA commercial clinical trial starts in 2018-2023

Country	2018	2019	2020	2021	2022	2023	2018-2023 CAGR
Austria	148	171	160	195	163	111	-5.6%
Belgium	305	308	294	345	307	218	-6.5%
Bulgaria	128	137	147	147	147	110	-3.0%
Croatia	45	35	31	32	38	31	-7.2%
Cyprus	1	2	2	1	2	1	0.0%
Czech Republic	199	233	196	251	216	147	-5.9%
Denmark	156	165	159	199	171	118	-5.4%
Estonia	39	40	47	37	35	24	-9.3%
Finland	86	81	53	90	61	54	-8.9%
France	439	485	466	568	518	389	-2.4%
Germany	618	600	580	665	623	417	-7.6%
Greece	105	108	133	146	151	106	0.2%
Hungary	205	216	204	264	218	161	-4.7%
Iceland	Limited coverage						

Note: Phase 1-4 commercial trials. Medical device trials and terminated/suspended trials were excluded  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# EEA markets and comparators (2/3)

Number of EEA commercial clinical trial starts in 2018-2023

Country	2018	2019	2020	2021	2022	2023	2018-2023 CAGR
Ireland	71	57	42	71	49	32	-14.7%
Italy	378	422	433	529	478	343	-1.9%
Latvia	44	42	42	40	35	30	-7.4%
Liechtenstein	Limited coverage						
Lithuania	49	45	42	32	39	33	-7.6%
Luxembourg	2	2	0	2	1	2	0.0%
Malta	Limited coverage						
Netherlands	282	284	290	350	313	210	-5.7%
Norway	60	59	54	87	79	57	-1.0%
Poland	332	367	344	491	406	300	-2.0%
Portugal	83	88	98	121	129	86	0.7%
Romania	94	98	88	99	105	80	-3.2%
Slovakia	65	78	68	79	73	69	1.2%
Slovenia	23	16	15	24	13	14	-9.5%

Note: Phase 1-4 commercial trials. Medical device trials and terminated/suspended trials were excluded

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)



# EEA markets and comparators (3/3)

Number of EEA commercial clinical trial starts in 2018-2023

Country	2018	2019	2020	2021	2022	2023	2018-2023 CAGR
Spain	491	544	548	688	607	485	-0.2%
Sweden	138	134	124	148	136	88	-8.6%
UK	566	528	495	630	566	437	-5.0%
Switzerland	117	111	112	137	118	104	-2.3%
EEA*	1253	1252	1277	1484	1282	920	-6.0%

Note: Phase 1-4 commercial trials. Medical device trials and terminated/suspended trials were excluded

\*Trials with sites in multiple EEA countries were counted once within EEA

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)



# EEA per capita performance

Commercial clinical trials in EEA countries per capita (100 000) in 2023

Country		#trials per capita
1	Denmark	2.00
2	Belgium	1.84
3	Bulgaria	1.72
4	Estonia	1.71
5	Hungary	1.68
6	Latvia	1.58
7	Czech Republic	1.35
8	Slovakia	1.28
9	Austria	1.22
10	Netherlands	1.17
11	Lithuania	1.14
12	Norway	1.04
13	Greece	1.02
14	Spain	1.00
15	Finland	0.96

Country		#trials per capita
16	Sweden	0.84
17	Portugal	0.82
18	Poland	0.82
19	Croatia	0.79
20	Slovenia	0.67
21	Ireland	0.60
22	Italy	0.58
23	France	0.57
24	Germany	0.49
25	Romania	0.42
26	Luxembourg	0.29
27	Cyprus	0.08
UK		0.64
Switzerland		1.22
US		0.51

Note: Limited data coverage on Lichtenstein, Malta and Iceland; Phase 1-4 commercial trials considered. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# EEA sub-regional performance

Number of EEA commercial clinical trial starts by region (Phase 1-4, 2018-2023)

Phase	2018	2019	2020	2021	2022	2023
Northern Europe	348	336	322	384	348	253
Central and Eastern Europe	469	493	447	616	509	421
Southern Europe	577	627	632	768	691	587
Western Europe	914	923	887	1,050	942	731
Total	2308	2379	2288	2818	2490	1992

Note: Medical device trials and terminated/suspended trials were excluded. Trial with sites in multiple regions were counted once per region.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# Global paediatric and paediatric/adult\* trials

No. global paediatric only + paediatric including adult population clinical trials by sponsor type (Phase 1-4, 2018-2024)

Sponsor type	2018	2019	2020	2021	2022	2023
Non-commercial	1438	1619	1931	1773	1689	1658
Commercial	612	569	533	640	585	554
Combined	40	48	59	49	27	42
Total	2090	2236	2523	2462	2301	2254

Note: \*Trials enrolling both pediatric only population and mixed (pediatric and adult population). Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# Global and EEA paediatric-only trials

Number of paediatric-only clinical trial starts by phase (2013, 2018-2023)

Global trial starts							
Phase	2013	2018	2019	2020	2021	2022	2023
Phase 1	65	78	103	137	160	137	143
Phase 2	215	287	262	302	317	300	287
Phase 3	208	205	245	259	268	253	283
Phase 4	119	138	168	139	164	165	161
Total	607	708	778	837	909	855	874

EEA trial starts							
Phase	2013	2018	2019	2020	2021	2022	2023
Phase 1	13	3	7	3	6	3	5
Phase 2	39	38	23	25	30	38	27
Phase 3	57	52	48	42	48	48	33
Phase 4	33	12	17	11	15	12	10
Total	142	105	95	81	99	101	75

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded. Trial with sites in multiple EEA countries were counted once within EEA.  
Source: Clinical Trial Repository (Access Date: June 12<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# EEA paediatric trials, commercial vs. non commercial

Number of EEA paediatric-only clinical trial starts by phase (2013, 2018-2023)

Commercial trial starts							
Sponsor type	2013	2018	2019	2020	2021	2022	2023
Phase 1	10	2	5	2	5	2	4
Phase 2	21	21	15	13	14	24	17
Phase 3	43	36	42	34	38	40	28
Phase 4	11	4	10	4	4	5	2
Total	85	63	72	53	61	71	51

Non-commercial trial starts							
Sponsor type	2013	2018	2019	2020	2021	2022	2023
Phase 1	3	1	2	1	1	1	1
Phase 2	19	19	9	14	19	15	10
Phase 3	17	17	8	11	11	9	6
Phase 4	25	8	7	7	11	7	8
Total	64	45	26	33	42	32	25

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# Paediatric trials global therapeutic area split

Global commercial paediatric trial starts, 2023 (Phases 1-4, top 10 TAs, n=214)		
Therapeutic area	Number of trial starts	%share
Infectious Disease (vaccines)	61 (43)	26%
Medical Genetics - Rare	31	13%
Endocrinology	18	8%
Gastrointestinal	17	7%
Psychiatry	16	7%
Neurology	16	7%
Dermatology	12	5%
Respiratory	11	5%
Rheumatology	9	4%
Hematology	9	4%
Other	33	14%

Commercial paediatric infectious disease vaccine trial starts, 2023		
Country	Number of trial starts	%share
China	13	23%
Japan	7	12%
United States	6	11%
South Africa	3	5%
India	3	5%
Philippines	2	4%
Poland	2	4%
Spain	2	4%
Indonesia	2	4%

Clinical trials assigned to multiple therapeutic areas are counted once per the therapeutic area. Clinical trials with sites in multiple countries are counted once per country.



# Global and EEA rare disease trials

Number of rare diseases clinical trial starts by phase (2013, 2018-2023)

Global trial starts							
Phase	2013	2018	2019	2020	2021	2022	2023
Phase 1	76	128	202	196	223	202	182
Phase 2	253	356	375	404	500	443	369
Phase 3	83	108	140	135	159	127	146
Phase 4	37	73	74	79	97	91	68
Total	449	665	791	814	979	863	765

EEA trial starts							
Phase	2013	2018	2019	2020	2021	2022	2023
Phase 1	12	13	16	16	9	8	8
Phase 2	64	73	74	64	87	65	50
Phase 3	33	35	48	29	57	31	29
Phase 4	9	15	9	12	10	11	7
Total	118	136	147	121	163	115	94

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded. Trial with sites in multiple EEA countries were counted once within EEA.  
Source: Clinical Trial Repository (Access Date: June 12<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# EEA commercial and non-commercial rare disease trials

Number of EEA commercial and non-commercial rare diseases clinical trial starts by phase (2013, 2018-2023)

Commercial trial starts							
Phase	2013	2018	2019	2020	2021	2022	2023
Phase 1	8	11	14	13	8	5	8
Phase 2	30	33	35	36	52	39	28
Phase 3	28	27	36	24	51	27	21
Phase 4	4	6	4	5	3	6	7
Total	70	77	89	78	114	77	64

Non-commercial trial starts							
Phase	2013	2018	2019	2020	2021	2022	2023
Phase 1	4	2	2	4	2	3	0
Phase 2	38	42	42	33	36	34	23
Phase 3	8	12	22	9	12	6	12
Phase 4	5	9	5	7	7	6	0
Total	55	65	71	53	57	49	35

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded. Trial with sites in multiple EEA countries were counted once within EEA. Due to data labelling, sum of trials across phases may not combine to same total as when counted by other dimensions

Source: Clinical Trial Repository (Access Date: June 12<sup>th</sup> 2024)

IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024

# Regional shares of Cell and Gene Therapy Trials

Share of commercial and non-commercial CaGT clinical trial starts by region (2013, 2018-2023)

Commercial trial starts							
Phase	2013	2018	2019	2020	2021	2022	2023
North America	48%	48%	43%	45%	37%	38%	41%
China	10%	34%	38%	40%	45%	47%	42%
Europe	25%	22%	15%	14%	13%	12%	10%
Rest of Asia	15%	12%	9%	12%	10%	10%	7%
Rest of World	6%	8%	5%	7%	8%	7%	10%
Japan	7%	7%	7%	4%	4%	3%	2%

Non-commercial trial starts							
Phase	2013	2018	2019	2020	2021	2022	2023
North America	39%	30%	27%	24%	21%	23%	35%
China	13%	39%	41%	41%	42%	47%	43%
Europe	20%	18%	19%	14%	15%	12%	7%
Rest of Asia	9%	4%	5%	6%	7%	8%	6%
Rest of World	10%	4%	6%	12%	12%	8%	9%
Japan	13%	6%	4%	4%	4%	3%	1%

Note: Due to trials being conducted in multiple countries and regions, the sum of shares across regions is greater than 100%.  
 Source: Strengthening Pathways for Cell and Gene Therapies, IQVIA Institute  
 IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024









## Pillar 2

# Clinical trial enrollment: patient numbers (global)

Total patient number in global commercial EEA and EEA-included trials (2018-2023)

Clinical trial location	2018	2019	2020	2021	2022	2023
Total patients on clinical trials (globally)	656 816	687 714	742 024	887 379	822 306	733 476
Total patients on trials which include an EEA site	286 159	292 456	298 962	332 935	310 136	226 155
Total patients in EEA-only trials	107 840	118 719	125 454	113 281	114 133	89 128

Median number of patients enrolled per trial (2018-2024)

Therapeutic area	 EEA	 CN	 US	 KOR	 JP	 AU
Rare diseases	32	62	50	65	37	36
Infectious diseases	72	148	86	87	142	53
Oncology	70	79	61	50	48	30

# Clinical trial enrollment: patient numbers (EEA deep dive)

*Median number of patients enrolled in oncology trials  
(2018-2023, EU4+ countries leading in CT numbers in EU + 3 comparator countries)*

Therapeutic area	FR	BE	IT	DE	ES	NL	PL	DK	US	UK	CH
Rare diseases	75	15	25	43	103	16	40	8	50	24	45
Infectious diseases	104	72	89	166	100	50	60	80	86	60	210
Oncology	132	70	60	54	52	50	41	27	61	41	30

*Mean number of patients enrolled in infectious diseases trials  
(2018-2023, EU4+ countries leading in CT numbers in EU + 3 comparator countries)*

Therapeutic area	FR	BE	IT	DE	ES	NL	PL	DK	US	UK	CH
Rare diseases	97	109	59	66	103	36	40	8	99	27	45
Infectious diseases	435	123	467	682	176	203	50	133	2506	635	333
Oncology	221	136	104	149	99	105	76	148	151	111	54



# Global enrolment speeds (1/2)

Region/Country	First patient in		Enrolment duration		Enrolment rate	
	Median days	# trials	Median months	# trials	Median	# trials
Oncology						
EEA	67	100+	22.7	100+	0.1	100+
Australia	58	20+	22.9	20+	0.1	20+
China	20	20+	17.3	20+	0.3	20+
Japan	69	20+	22.0	20+	0.2	20+
South Korea	28	20+	24.6	20+	0.1	20+
US	104	100+	23.0	1000+	0.2	1000+
Rare diseases						
EEA	36	100+	17.7	20+	0.2	20+
Australia	42	20+	14.7	20+	0.2	20+
China	Limited coverage	-	9.0	20+	0.4	20+
Japan	12	20+	14.9	20+	0.2	20+
South Korea	Limited coverage	-	27.6	20+	0.1	20+
US	Limited coverage	-	20.8	100+	0.1	100+





# Global enrolment speed (2/2)

Region/Country	First patient in		Enrolment duration		Enrolment rate	
	Median days	# trials	Median months	# trials	Median	N trials
Infectious diseases						
EEA	5	100+	7.9	100+	1.4	100+
Australia	11	20+	8.0	20+	1.8	20+
China	86	20+	3.6	20+	17.9	20+
Japan	16	20+	7.6	20+	2.6	20+
South Korea	Limited coverage	-	8.7	20+	1.3	20+
US	4	100+	7.8	1000+	1.9	1000+
Vaccines (Prophylactic + anticancer + recombinant vaccine)						
EEA	1	20+	7.9	20+	3.2	20+
Australia	6	20+	8.8	20+	3.3	20+
China	Limited coverage	-	3.9	20+	103.9	20+
Japan	Limited coverage	-	7.8	<10	3.2	20+
South Korea	Limited coverage	-	7.6	20+	2.9	20+
US	38	< 10	4.1	20+	15.1	20+
Vaccines (Therapeutic)						
EEA	1	20+	7.9	20+	1.6	20+
Australia	6	20+	9.2	20+	3.2	20+
China	Limited coverage	-	3.8	20+	33.6	20+
Japan	Limited coverage	-	8.3	<10	6.9	20+
South Korea	Limited coverage	-	14.5	20+	0.9	20+
US	38	<10	3.5	20+	7.0	20+



# Oncology EEA country level enrollment (1/2)

Region/Country	First patient in		Enrolment duration		Enrolment rate	
	Median days	N trials	Median months	N trials	Median	N trials
<b>Austria</b>	Limited coverage	-	22.3	20+	0.1	20+
<b>Belgium</b>	Limited coverage	-	23.1	20+	0.1	20+
<b>Bulgaria</b>	Limited coverage	-	21.4	20+	0.1	20+
<b>Croatia</b>	Limited coverage	-	28.0	<20	0.1	20+
<b>Cyprus</b>	Limited coverage	-	24.0	<5	14.6	<5
<b>Czech Rep.</b>	50	20+	22.6	20+	0.1	20+
<b>Denmark</b>	49	20+	23.3	20+	0.1	20+
<b>Estonia</b>	Limited coverage	-	23.7	20+	0.2	20+
<b>Finland</b>	Limited coverage	-	26.3	20+	0.1	20+
<b>France</b>	117.5	20+	23.0	20+	0.1	20+
<b>Germany</b>	82	20+	23.3	20+	0.1	20+
<b>Greece</b>	Limited coverage	-	25.4	20+	0.1	20+
<b>Hungary</b>	Limited coverage	-	23.0	20+	0.1	20+
<b>Iceland</b>	Limited coverage	-	11.5	<5	0.1	<5
<b>Italy</b>	85	20+	22.8	20+	0.1	20+



# Oncology EEA country level enrollment (2/2)

Region/Country	First patient in		Enrolment duration		Enrolment rate	
	Median days	N trials	Median months	N trials	Median	N trials
Latvia	Limited coverage	-	18.9	<15	0.1	20+
Liechtenstein	Limited coverage	-	Limited coverage	-	Limited coverage	-
Lithuania	Limited coverage	-	22.4	20+	0.2	20+
Luxembourg	Limited coverage	-	33.2	<5	0.3	20+
Malta	Limited coverage	-	Limited coverage	-	Limited coverage	-
Netherlands	103	20+	24.7	<10	0.1	20+
Norway	Limited coverage	-	27.5	20+	0.1	20+
Poland	14	<5	22.8	20+	0.1	20+
Portugal	Limited coverage	-	26.0	20+	0.1	20+
Romania	Limited coverage	-	24.0	20+	0.1	20+
Slovakia	Limited coverage	-	21.2	20+	0.1	20+
Slovenia	Limited coverage	-	31.4	<10	0.1	20+
Spain	41	20+	23.3	20+	0.1	20+
Sweden	Limited coverage	-	25.5	20+	0.1	20+
UK	43	20+	23.3	20+	0.1	20+
Switzerland	Limited coverage	-	23.2	20+	0.1	20+

# Infectious diseases EEA country level enrollment (1/2)

Region/Country	First patient in		Enrolment duration		Enrolment rate	
	Median days	N trials	Median months	N trials	Median	N trials
<b>Austria</b>	Limited coverage	-	11.3	20+	0.6	20+
<b>Belgium</b>	1	<10	7.3	20+	1.0	20+
<b>Bulgaria</b>	Limited coverage	-	14.6	20+	0.3	20+
<b>Croatia</b>	Limited coverage	-	21.8	<15	0.4	<15
<b>Cyprus</b>	Limited coverage	-	2.1	<5	3.9	<5
<b>Czech Rep.</b>	Limited coverage	-	16.4	20+	0.3	20+
<b>Denmark</b>	22.5	<10	6.6	20+	0.9	20+
<b>Estonia</b>	1	<10	14.7	20+	1.0	20+
<b>Finland</b>	Limited coverage	-	8.9	20+	2.5	20+
<b>France</b>	2.5	<10	9.8	20+	0.5	20+
<b>Germany</b>	1	20+	8.4	20+	0.8	20+
<b>Greece</b>	Limited coverage	-	16.6	20+	0.3	20+
<b>Hungary</b>	Limited coverage	-	16.6	20+	0.3	20+
<b>Iceland</b>	Limited coverage	-	1.5	<5	71.5	<5
<b>Italy</b>	Limited coverage	-	8.9	20+	0.6	20+

## Infectious diseases EEA country level enrollment (2/2)

Region/Country	First patient in		Enrolment duration		Enrolment rate	
	Median days	N trials	Median months	N trials	Median	N trials
<b>Latvia</b>	Limited coverage	-	16.8	20+	0.2	20+
<b>Liechtenstein</b>	Limited coverage	-	Limited coverage	-	Limited coverage	-
<b>Lithuania</b>	Limited coverage	-	17.0	20+	0.3	20+
<b>Luxembourg</b>	Limited coverage	-	13.6	20+	0.93	20+
<b>Malta</b>	Limited coverage	-	Limited coverage	-	Limited coverage	-
<b>Netherlands</b>	Limited coverage	-	7.5	20+	1.5	20+
<b>Norway</b>	Limited coverage	-	17.0	20+	1.1	20+
<b>Poland</b>	11	<15	10.3	20+	0.5	20+
<b>Portugal</b>	Limited coverage	-	16.0	20+	0.2	20+
<b>Romania</b>	98	<10	13.6	20+	0.4	20+
<b>Slovakia</b>	Limited coverage	-	17.0	20+	0.4	20+
<b>Slovenia</b>	Limited coverage	-	7.1	<5	5.9	<5
<b>Spain</b>	7	20+	9.0	20+	0.7	20+
<b>Sweden</b>	Limited coverage	-	13.3	20+	0.9	20+
<b>UK</b>	11	<20	8.4	20+	1.2	20+
<b>Switzerland</b>	Limited coverage	-	6.5	20+	1.0	20+



# Immunisation trials



# Total immunisation trials by sponsor (by region)

Number of global immunisation clinical trial starts by sponsor type (2018-2023; Phase 1-4)

Sponsor type	2018	2019	2020	2021	2022	2023
Non-commercial	244	218	354	574	358	224
Commercial	193	227	296	416	359	269
Combined	49	61	95	110	87	76
<b>Total</b>	<b>486</b>	<b>506</b>	<b>745</b>	<b>1100</b>	<b>804</b>	<b>569</b>

Number of commercial + combined clinical trial starts in top 10 countries (2018, 2023; Phase 1-4)

Country	2018	2023	2018-2023 CAGR
US	87	109	5%
China	34	72	16%
Japan	14	32	18%
Australia	17	26	9%
UK	14	23	10%
Germany	24	19	-5%
Spain	17	19	2%
Canada	15	19	5%
India	17	18	1%
Philippines	4	17	34%

Note: Combined sponsors: any trials with more than one type of sponsor (non-commercial, EBPs, mid pharma, large pharma); Medical device trials and terminated/suspended trials were excluded. Clinical trials with sites in multiple countries were counted on ce per each country, meaning totals may not sum to same value as when counted by other dimensions

Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)



# Trials by phase (commercial vs. non commercial split)

*Commercial and non-commercial immunisation trial starts by phase (2018-2023)*

Commercial trial starts						
Phase	2018	2019	2020	2021	2022	2023
Phase 1	55	83	120	130	120	112
Phase 2	92	84	130	180	130	119
Phase 3	70	96	115	147	155	87
Phase 4	25	25	26	69	41	27
Total	242	288	391	526	446	345

Non-commercial trial starts						
Phase	2018	2019	2020	2021	2022	2023
Phase 1	72	74	84	132	114	82
Phase 2	101	75	147	210	117	70
Phase 3	20	22	78	92	57	31
Phase 4	51	47	45	140	70	41
Total	244	218	354	574	358	224

Note: Combined sponsors: any trials with more than one type of sponsor (non-commercial, EBPs, mid pharma, large pharma); Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024





# EEA commercial immunisation starts

Number of EEA commercial immunisation clinical trial starts in 2018-2023

Country	2018	2023
Austria	2	0
Belgium	14	8
Bulgaria	2	2
Croatia	Limited coverage	
Cyprus	Limited coverage	
Czech Republic	4	1
Denmark	2	6
Estonia	4	2
Finland	11	3
France	14	12
Germany	24	19
Greece	1	1
Hungary	6	1
Iceland	Limited coverage	

Country	2018	2023
Ireland	Limited coverage	
Italy	8	8
Latvia	0	1
Liechtenstein	Limited coverage	
Lithuania	0	1
Luxembourg	Limited coverage	
Malta	Limited coverage	
Netherlands	6	5
Norway	4	2
Poland	7	7
Portugal	Limited coverage	
Romania	1	1
Slovakia	1	1
Slovenia	Limited coverage	

Country	2018	2023
Spain	17	19
Sweden	7	4

Note: Phase 1-4 commercial trials. Medical device trials and terminated/suspended trials were excluded Clinical trials with sites in multiple countries were counted once per each country.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024



# EEA phase split

Number of EEA commercial clinical trial starts by phase (2018-2023; Phase 1-4)

Phase	2018	2019	2020	2021	2022	2023
Phase 1	4	6	8	7	9	6
Phase 2	20	14	17	30	18	15
Phase 3	14	16	17	24	23	7
Phase 4	4	1	4	14	4	0
Total	42	37	46	75	54	28

Note: Phase 2 includes Phase 1/2, 2a & 2b trials, Phase 3 includes Phase 2/3. Medical device trials and terminated/suspended trials were excluded.  
Source: Clinical Trial Repository (Access Date: April 30<sup>th</sup> 2024)  
IQVIA | EFPIA-VE | Assessing the Clinical Trial Ecosystem in Europe | Final Report | August 2024